Chronic hepatitis C infection affects over 180 million people worldwide and is the major cause of liver cancer and liver transplantation in the Western countries. Recent advances in the therapeutics for HCV has revolutionized the management of patients infected with hepatitis C virus. These new wave of paradigm shift in therapeutics from an injectable interferon based long term treatment with several adverse events with modest efficacy to all oral, simple short duration therapy that can cure almost all treated patients. However, the cost of the medications, lack of awareness of the diagnosis, and insufficient number of providers treating hepatitis C with new agents: all pose challenges in eradicating HCV infection. In this mini symposium, we address the major challenges that we face today in managing HCV infection including health economics, redefining difficult to treat patients and highlight the pathway to move forward.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.